The 2022 ASCO Annual Meeting took place last week in Chicago. This week, we're featuring conversations on two high-profile studies in breast cancer and colon cancer presented at the meeting. To listen to more podcasts from ASCO, visit asco.org/podcasts .
Last week, the FDA approved treatments for esophageal cancer and follicular lymphoma. On this episode, we'll review the data supporting those approvals and hear from researchers involved in the trials investigating the efficacy of these regimens. Coverage of stories discussed this week on ascopost.com: FDA Approves Two Nivolumab-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma FDA Approves Tisagenlecleucel for Adult Patients With ...
This week, we're covering the FDA approval of a doublet therapy in certain populations of patients with newly diagnosed acute myeloid leukemia. Then we'll hear about a comparison study of treatments for patients with metastatic breast cancer and brain metastases. Coverage of stories discussed this week on ascopost.com: FDA Approves Ivosidenib/Azacitidine for Certain Patients With Newly Diagnosed AML Etirinotecan Pegol vs Physician's Choice of Chemotherapy for Patients With Metastatic Breast Canc...
The Society of Gynecologic Oncology Annual Meeting on Women's Cancer was held recently in Phoenix, Arizona. On this episode, we'll hear from two researchers who presented data at the meeting on ovarian and cervical cancers. To listen to more podcasts from ASCO, visit asco.org/podcasts .
On this episode, we'll be discussing an updated overall survival analysis from the MONALEESA-3 trial presented at the ESMO Breast Cancer Congress 2022. Then, we'll hear from a researcher about the current state of cancer research and anticipated trends in the field. Coverage of stories discussed this week on ascopost.com: Updated Overall Survival Results From MONALEESA-3 Show Improved Overall Survival in Patients With HR-Positive/HER2-Negative Breast Cancer To listen to more podcasts from ASCO, ...
On May 4, the FDA approved fam-trastuzumab deruxtecan-nxki for pretreated adult patients with unresectable or metastatic HER2-positive breast cancer. We highlight findings from the DESTINY-Breast03 trial that led to the regular approval, and also hear from Dr. Sara Hurvitz, of the University of California, Los Angeles Jonsson Comprehensive Cancer Center, who discussed the trial results with The ASCO Post at the 2021 San Antonio Breast Cancer Symposium. Coverage of stories discussed this week on ...
On this episode, we'll continue our coverage of the American Association for Cancer Research, or AACR, Annual Meeting. We'll hear from three specialists on the future of cancer research and treatment; the development of novel therapeutic strategies to target DNA damage response; and an overview of the FDA's accelerated approval program. To listen to more podcasts from ASCO, visit asco.org/podcasts .
The NCCN 2022 Annual Conference took place from March 30 to April 1 as a virtual event. Designed to meet the educational needs of the interprofessional oncology care team, the conference offered more than 30 educational sessions featuring the latest advances and experts in oncology care. On this episode of the podcast, we'll hear from three speakers who discussed recent advances in cancer care in their respective fields. To listen to more podcasts from ASCO, visit asco.org/podcasts ....
In this week's episode, we are discussing two recent FDA approvals—one for prostate cancer, and the other for endometrial cancer. The radioconjugate lutetium Lu-177 vipivotide tetraxetan was approved for the treatment of adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. Pembrolizumab was approved as a single agent for patients with advanced ...
In this week's episode, we'll discuss a recent FDA approval in germline BRCA -mutated, HER2-negative, high-risk early breast cancer. Then, we'll hear about the publication of final overall survival results from the MONALEESA-2 trial, which evaluated the efficacy of the addition of ribociclib to letrozole in the first-line treatment of postmenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer. Coverage of stories discussed this week on ascopost.com: FDA Approves Ol...
In this week's episode, we'll discuss a recent U.S. Food and Drug Administration (FDA) approval in the early-stage non–small cell lung cancer setting. Then, we'll hear about a study presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium that investigated methods for the de-escalation of radiation therapy for oropharyngeal cancer. Coverage of stories discussed this week on ascopost.com: FDA Approves Neoadjuvant Nivolumab and Platinum Doublet Chemotherapy for Early-Stage NSCLC Mid...
The 2022 Multidisciplinary Head and Neck Cancers Symposium took place from February 24 to 26 in Phoenix, Arizona. The meeting provided the most up-to-date information on multidisciplinary therapies, clinical research, treatment strategies, supportive care, and scientific breakthroughs in head and neck cancer. On this episode of the podcast, we'll hear from three authors who presented their research at the meeting. To listen to more podcasts from ASCO, visit asco.org/podcasts ....
In this episode, we're highlighting three presentations from the ASCO Genitourinary Cancers Symposium, held recently in San Francisco. To listen to more podcasts from ASCO, visit asco.org/podcasts .
The 2022 ASCO Genitourinary Cancers Symposium kicked off this week. On this episode, we'll hear about two studies presented at the meeting: one, focused on a genetic risk score that may aid in identifying men with high vs low lifetime risks of developing metastatic prostate cancer or dying from prostate cancer; and the second, about a trial that tested the efficacy of combination immunotherapy and tyrosine kinase inhibitor therapy for renal cell carcinoma. Coverage of stories discussed this week...
In this episode, we'll review a report on the KRYSTAL-1 trial of adagrasib therapy in various gastrointestinal cancers, and highlight key points from the newly released AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care. Coverage of stories discussed this week on ascopost.com: KRYSTAL-1: Adagrasib Controls Disease in Gastrointestinal Malignancies Beyond Colorectal Cancer AACR Releases Report on the Impact of COVID-19 on Cancer Research and Patient Care To listen to more po...
This week, we're reviewing a statement issued by the White House earlier this week on the Cancer Moonshot initiative. Coverage of stories discussed this week on ascopost.com: President Biden Reignites Cancer Moonshot To listen to more podcasts from ASCO, visit asco.org/podcasts .
On this episode, we'll be talking about an FDA approval for uveal melanoma, as well as the efficacy of PD-1 inhibition in patients with resectable liver cancer. Coverage of stories discussed this week on ascopost.com: FDA Approves Tebentafusp-tebn for the Treatment of Unresectable or Metastatic Uveal Melanoma Neoadjuvant Cemiplimab-rwlc for Patients With Resectable Hepatocellular Carcinoma To listen to more podcasts from ASCO, visit asco.org/podcasts ....
The 2022 ASCO Gastrointestinal Cancers Symposium took place in San Francisco from January 20 to 22. This week, we're featuring commentary from the authors involved in two high-impact studies in hepatobiliary cancers. To listen to more podcasts from ASCO, visit asco.org/podcasts .
On this episode, we'll hear about a combination therapy that improved progression-free survival in previously untreated patients with melanoma. Then, we'll hear about a report that looked into the effects of prior radiotherapy on the development of adverse events in patients treated with immune checkpoint inhibitors. Coverage of stories discussed this week on ascopost.com: Addition of Anti–LAG-3 Antibody Relatlimab to Nivolumab in Previously Untreated Patients With Advanced Melanoma Effect of Re...
On this episode, we're discussing a phase III trial that showed improved progression-free survival with VEGFR2 inhibition in certain patients with thyroid cancer. Then, we'll hear about a report on outcomes of breakthrough COVID-19 infection among fully vaccinated patients with cancer. Coverage of stories discussed this week on ascopost.com: Apatinib for Advanced Radioactive Iodine–Refractory Differentiated Thyroid Cancer Study Finds Fully Vaccinated Patients With Cancer and Breakthrough COVID-1...
The 2021 ASH Annual Meeting & Exposition took place from December 11-14. This week, we're highlighting two studies featured as late-breaking abstracts at the meeting. To listen to more podcasts from ASCO, visit asco.org/podcasts .
The San Antonio Breast Cancer Symposium was held from December 7 to 10. On this episode, we'll hear from three authors of high-impact research that was presented during the meeting. To listen to more podcasts from ASCO, visit asco.org/podcasts .
The Society for Immunotherapy of Cancer (or SITC) held its Annual Meeting from November 10 to November 14. This week, we'll hear from two researchers who presented data at SITC. To listen to more podcasts from ASCO, visit asco.org/podcasts .
The National Comprehensive Cancer Network's 2021 Virtual Congress on Hematologic Malignancies took place from October 14 to October 16. The meeting focused on updates to the NCCN Guidelines; new, emerging, and novel therapeutic agents; advances in cancer care; and the practical management of patients with hematologic malignancies. This week, we hear from three presenters who participated in the conference. To listen to more podcasts from ASCO, visit asco.org/podcasts ....
This week, we're reviewing research highlights in prostate cancer that were presented at the 2021 ASTRO Annual Meeting. We'll hear from three presenting authors on the role of radiotherapy in combination with androgen-deprivation therapy, androgen suppression, and surgery. To listen to more podcasts from ASCO, visit asco.org/podcasts .
The 2021 ASTRO Annual Meeting took place in Chicago from October 24 to October 27. This week, we're hearing from authors of three late-breaking abstracts. The research focuses on the role of radiotherapy in HPV-associated oropharyngeal cancer, as well as in oligoprogressive lung and breast cancers. To listen to more podcasts from ASCO, visit asco.org/podcasts .
Recently, Dr. Govind Persad, of the University of Denver Sturm College of Law, wrote an op-ed for The ASCO Post entitled " Oncology Care Remains Under Strain in the Ongoing COVID-19 Pandemic ." On this episode of the podcast, Dr. Persad further discusses the challenges that patients with cancer and their physicians face surrounding COVID-19, as well as some possible solutions. As hospitals and providers have coped with those in urgent need of care, the question of how to prioritize cancer treatm...
This week, the FDA approved new indications for two drugs. The first approval was for abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer who are at high risk of disease recurrence and who also have a Ki67 score of 20% or higher. The next day, the agency approved pembrolizumab in combination with chemotherapy, with or without bevacizum...
This week, we're hearing about lung cancer data from the ESMO Congress 2021—specifically, a novel tyrosine kinase inhibitor for HER2 exon 20–mutated non–small cell lung cancer, and a second-line vaccine for HLA-A2–positive disease. To listen to more podcasts from ASCO, visit asco.org/podcasts .
This week, we explore more findings presented during the virtual ESMO Congress 2021—specifically, data in genitourinary oncology. We'll hear from researchers on the efficacy and safety of abiraterone acetate added to different regimens for different types of prostate cancer, as well as patient-reported quality of life with adjuvant pembrolizumab vs placebo for renal cell carcinoma. To listen to more podcasts from ASCO, visit asco.org/podcasts ....
